Floatz logo

ik-595

Ras (Kras or Nras) Gene Mutation

Ikena OncologyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Ras (Kras or Nras) Gene Mutation cohort.

Asset / SponsorPhaseRating
Binimetinib
N.N. Petrov National Medical Research Center of Oncology
Phase 2CCC
Cobimetinib
N.N. Petrov National Medical Research Center of Oncology
Phase 2CCC
Hydroxychloroquine
N.N. Petrov National Medical Research Center of Oncology
Phase 2CCC
Leflunomide
N.N. Petrov National Medical Research Center of Oncology
Phase 2CCC
gsk1120212
N.N. Petrov National Medical Research Center of Oncology
Phase 2CCC

Same molecule, other indications

ik-595 is also rated in:

BRAF Gene MutationDormant
CC
Indicative ·
43 / 100
View asset →
CRAF Gene MutationDormant
CC
Indicative ·
43 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →